Top

Published in:

01-07-2016 | Original Article

Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas

Authors: Taiichi Saito, Yoshihiro Muragaki, Takashi Maruyama, Takashi Komori, Manabu Tamura, Masayuki Nitta, Shunsuke Tsuzuki, Takakazu Kawamata

Published in: Brain Tumor Pathology | Issue 3/2016

Abstract

Gliomas with 1p/19q loss of heterozygosity (LOH) are known to be associated with longer patient survival and higher sensitivity to treatment than tumors without 1p/19q LOH. This study was designed to clarify whether the preoperative finding of calcification on CT was correlated with 1p/19q LOH in patients with suspected WHO grade II and III gliomas. This study included 250 adult patients who underwent resection for primary supratentorial tumors at Tokyo Women’s Medical University Hospital. The tumors were suspected, based on MRI findings, to be WHO grade II or III gliomas. The presence of calcification on the patients’ CT images was qualitatively evaluated before treatment. After surgery, the resected tumors were examined to determine their 1p/19q status and mutations of IDH1 and p53. The presence of calcification was significantly correlated with 1p/19q LOH (P < 0.0001), with a positive predictive value of 91 %. The tumors of all the 78 patients with calcification were diagnosed as oligodendroglial tumors. Seventy of these patients showed classic oligodendroglial features, while 8 patients showed non-classic features. Calcification on CT is a simple and valuable preoperative indicator of 1p/19q LOH in supratentorial brain tumors that are suspected to be WHO grade II and III gliomas.

Bourne TD, Schiff D (2010) Update on molecular findings, management and outcome in low-grade gliomas. Nat Rev Neurol 6:695–701CrossRefPubMed

Cairncross G, Jenkins R (2008) Gliomas with 1p/19q codeletion: a.k.a. oligodendroglioma. Cancer J 14:352–357CrossRefPubMed

Jenkins RB, Blair H, Ballman KV, Giannini C, Arusell RM, Law M, Flynn H, Passe S, Felten S, Brown PD, Shaw EG, Buckner JC (2006) A t(1;19)(q10;p10) mediates the combined deletions of 1p and 19q and predicts a better prognosis of patients with oligodendroglioma. Cancer Res 66:9852–9861CrossRefPubMed

Giannini C, Burger PC, Berkey BA, Cairncross JG, Jenkins RB, Mehta M, Curran WJ, Aldape K (2008) Anaplastic oligodendroglial tumors: refining the correlation among histopathology, 1p 19q deletion and clinical outcome in Intergroup Radiation Therapy Oncology Group Trial 9402. Brain Pathol 18:360–369CrossRefPubMed

Watanabe T, Nobusawa S, Kleihues P, Ohgaki H (2009) IDH1 mutations are early events in the development of astrocytomas and oligodendrogliomas. Am J Pathol 174:1149–1153CrossRefPubMedPubMedCentral

Reifenberger J, Reifenberger G, Liu L, James CD, Wechsler W, Collins VP (1994) Molecular genetic analysis of oligodendroglial tumors shows preferential allelic deletions on 19q and 1p. Am J Pathol 145:1175–1190PubMedPubMedCentral

Fellah S, Caudal D, De Paula AM, Dory-Lautrec P, Figarella-Branger D, Chinot O, Metellus P, Cozzone PJ, Confort-Gouny S, Ghattas B, Callot V, Girard N (2013) Multimodal MR imaging (diffusion, perfusion, and spectroscopy): is it possible to distinguish oligodendroglial tumor grade and 1p/19q codeletion in the pretherapeutic diagnosis? AJNR Am J Neuroradiol 34:1326–1333CrossRefPubMed

Jenkinson MD, du Plessis DG, Smith TS, Joyce KA, Warnke PC, Walker C (2006) Histological growth patterns and genotype in oligodendroglial tumours: correlation with MRI features. Brain 129:1884–1891CrossRefPubMed

Megyesi JF, Kachur E, Lee DH, Zlatescu MC, Betensky RA, Forsyth PA, Okada Y, Sasaki H, Mizoguchi M, Louis DN, Cairncross JG (2004) Imaging correlates of molecular signatures in oligodendrogliomas. Clin Cancer Res 10:4303–4306CrossRefPubMed

10.

Whitmore RG, Krejza J, Kapoor GS, Huse J, Woo JH, Bloom S, Lopinto J, Wolf RL, Judy K, Rosenfeld MR, Biegel JA, Melhem ER, O’Rourke DM (2007) Prediction of oligodendroglial tumor subtype and grade using perfusion weighted magnetic resonance imaging. J Neurosurg 107:600–609CrossRefPubMed

11.

Jansen NL, Schwartz C, Graute V, Eigenbrod S, Lutz J, Egensperger R, Popperl G, Kretzschmar HA, Cumming P, Bartenstein P, Tonn JC, Kreth FW, la Fougere C, Thon N (2012) Prediction of oligodendroglial histology and LOH 1p/19q using dynamic [(18)F]FET-PET imaging in intracranial WHO grade II and III gliomas. Neuro-oncology 14:1473–1480CrossRefPubMedPubMedCentral

12.

Walker C, du Plessis DG, Fildes D, Haylock B, Husband D, Jenkinson MD, Joyce KA, Broome J, Kopitski K, Prosser J, Smith T, Vinjamuri S, Warnke PC (2004) Correlation of molecular genetics with molecular and morphological imaging in gliomas with an oligodendroglial component. Clin Cancer Res 10:7182–7191CrossRefPubMed

13.

Saito T, Maruyama T, Muragaki Y, Tanaka M, Nitta M, Shinoda J, Aki T, Iseki H, Kurisu K, Okada Y (2013) 11C-methionine uptake correlates with combined 1p and 19q loss of heterozygosity in oligodendroglial tumors. AJNR Am J Neuroradiol 34:85–91CrossRefPubMed

14.

Lee YY, Van Tassel P (1989) Intracranial oligodendrogliomas: imaging findings in 35 untreated cases. AJR Am J Roentgenol 152:361–369CrossRefPubMed

15.

Leonardi MA, Lumenta CB (2001) Oligodendrogliomas in the CT/MR-era. Acta Neurochir (Wien) 143:1195–1203CrossRef

16.

Shaw EG, Scheithauer BW, O’Fallon JR, Tazelaar HD, Davis DH (1992) Oligodendrogliomas: the Mayo Clinic experience. J Neurosurg 76:428–434CrossRefPubMed

17.

Zulfiqar M, Dumrongpisutikul N, Intrapiromkul J, Yousem DM (2012) Detection of intratumoral calcification in oligodendrogliomas by susceptibility-weighted MR imaging. AJNR Am J Neuroradiol 33:858–864CrossRefPubMed

18.

Martin F Jr, Lemmen LJ (1952) Calcification in intracranial neoplasms. Am J Pathol 28:1107–1131PubMedPubMedCentral

19.

Shimizu KT, Tran LM, Mark RJ, Selch MT (1993) Management of oligodendrogliomas. Radiology 186:569–572CrossRefPubMed

20.

Aldape K, Burger PC, Perry A (2007) Clinicopathologic aspects of 1p/19q loss and the diagnosis of oligodendroglioma. Arch Pathol Lab Med 131:242–251PubMed

21.

McDonald JM, See SJ, Tremont IW, Colman H, Gilbert MR, Groves M, Burger PC, Louis DN, Giannini C, Fuller G, Passe S, Blair H, Jenkins RB, Yang H, Ledoux A, Aaron J, Tipnis U, Zhang W, Hess K, Aldape K (2005) The prognostic impact of histology and 1p/19q status in anaplastic oligodendroglial tumors. Cancer 104:1468–1477CrossRefPubMed

22.

van den Bent MJ, Looijenga LH, Langenberg K, Dinjens W, Graveland W, Uytdewilligen L, Sillevis Smitt PA, Jenkins RB, Kros JM (2003) Chromosomal anomalies in oligodendroglial tumors are correlated with clinical features. Cancer 97:1276–1284CrossRefPubMed

23.

Khalid L, Carone M, Dumrongpisutikul N, Intrapiromkul J, Bonekamp D, Barker PB, Yousem DM (2012) Imaging characteristics of oligodendrogliomas that predict grade. AJNR Am J Neuroradiol 33:852–857CrossRefPubMedPubMedCentral

24.

Zou P, Xu H, Chen P, Yan Q, Zhao L, Zhao P, Gu A (2013) IDH1/IDH2 mutations define the prognosis and molecular profiles of patients with gliomas: a meta-analysis. PLoS One 8:e68782CrossRefPubMedPubMedCentral

25.

Durand KS, Guillaudeau A, Weinbreck N, DeArmas R, Robert S, Chaunavel A, Pommepuy I, Bourthoumieu S, Caire F, Sturtz FG, Labrousse FJ (2010) 1p19q LOH patterns and expression of p53 and Olig2 in gliomas: relation with histological types and prognosis. Modern Pathol 23:619–628CrossRef

26.

Louis DN, Ohgaki H, Wiestler OD, Cavenee WK, Burger PC, Jouvet A, Scheithauer BW, Kleihues P (2007) The 2007 WHO classification of tumours of the central nervous system. Acta Neuropathol 114:97–109CrossRefPubMedPubMedCentral

27.

Suzuki H, Aoki K, Chiba K, Sato Y, Shiozawa Y, Shiraishi Y, Shimamura T, Niida A, Motomura K, Ohka F, Yamamoto T, Tanahashi K, Ranjit M, Wakabayashi T, Yoshizato T, Kataoka K, Yoshida K, Nagata Y, Sato-Otsubo A, Tanaka H, Sanada M, Kondo Y, Nakamura H, Mizoguchi M, Abe T, Muragaki Y, Watanabe R, Ito I, Miyano S, Natsume A, Ogawa S (2015) Mutational landscape and clonal architecture in grade II and III gliomas. Nat Genet 47:458–468CrossRefPubMed

28.

Nitta M, Muragaki Y, Maruyama T, Ikuta S, Komori T, Maebayashi K, Iseki H, Tamura M, Saito T, Okamoto S, Chernov M, Hayashi M, Okada Y (2015) Proposed therapeutic strategy for adult low-grade glioma based on aggressive tumor resection. Neurosurg Focus 38:E7. doi:10.3171/2014.10.FOCUS14651 CrossRefPubMed

29.

Sanai N, Berger MS (2008) Glioma extent of resection and its impact on patient outcome. Neurosurgery 62:753–764 (discussion 264–756) CrossRefPubMed

30.

Schomas DA, Laack NN, Rao RD, Meyer FB, Shaw EG, O’Neill BP, Giannini C, Brown PD (2009) Intracranial low-grade gliomas in adults: 30-year experience with long-term follow-up at Mayo Clinic. Neuro-oncology 11:437–445CrossRefPubMedPubMedCentral

31.

Moriya J, Tanino MA, Takenami T, Endoh T, Urushido M, Kato Y, Wang L, Kimura T, Tsuda M, Nishihara H, Tanaka S,Group RIS (2016) Rapid immunocytochemistry based on alternating current electric field using squash smear preparation of central nervous system tumors. Brain tumor pathology 33:13–18CrossRef

32.

Tanino M, Sasajima T, Nanjo H, Akesaka S, Kagaya M, Kimura T, Ishida Y, Oda M, Takahashi M, Sugawara T, Yoshioka T, Nishihara H, Akagami Y, Goto A, Minamiya Y, Tanaka S, Group RIS (2015) Rapid immunohistochemistry based on alternating current electric field for intraoperative diagnosis of brain tumors. Brain tumor pathology 32:12–19CrossRef

Title: Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas
Authors: Taiichi Saito
Yoshihiro Muragaki
Takashi Maruyama
Takashi Komori
Manabu Tamura
Masayuki Nitta
Shunsuke Tsuzuki
Takakazu Kawamata
Publication date: 01-07-2016
Publisher: Springer Japan
Published in: Brain Tumor Pathology / Issue 3/2016
Print ISSN: 1433-7398
Electronic ISSN: 1861-387X
DOI: https://doi.org/10.1007/s10014-016-0249-5

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Calcification on CT is a simple and valuable preoperative indicator of 1p/19q loss of heterozygosity in supratentorial brain tumors that are suspected grade II and III gliomas

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 3/2016

A simplified approach for molecular classification of glioblastomas (GBMs): experience from a tertiary care center in India

Clinicopathological differences between variants of the NAB2–STAT6 fusion gene in solitary fibrous tumors of the meninges and extra-central nervous system

Activation of multiple angiogenic signaling pathways in hemangiopericytoma

Lipomatous ependymoma: report of a rare differentiation pattern with a comprehensive review of literature

Cancer metabolism as a central driving force of glioma pathogenesis

Lipomatous ependymoma: response to query on T1-weighted image